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Abstract 23 
Diosgenin, found in wild yam (Dioscorea villosa), has been shown to ameliorate diabetes 24 
and hyperlipidemia, increase cell proliferation in a human 3D skin model, and inhibit melanin 25 
production in B16 melanoma cells.  It is also an active element in cosmeceutical and dietary 26 
supplements.  Although the bioavailability of diosgenin is low due to its poor solubility and 27 
intestinal permeability, it was subsequently improved using a β-cyclodextrin (β-CD) inclusion 28 
complex.  Recently liquid crystals (LCs) were shown to enhance the bioavailability of poorly 29 
water-soluble drugs.  The purpose in the present study was to prepare diosgenin LCs and 30 
investigate the interaction between LC and β-CD in order to improve its bioavailability of 31 
diosgenin.  Crystallinity and particle diameters of LCs in water were determined by small 32 
angle X-ray scattering (SAXS) and Zetasizer.  Pharmacokinetic parameters were calculated 33 
using the plasma content of diosgenin after its oral administration to Wistar rats.  Regarding 34 
the formation of glyceryl monooleate (GMO) and phytantriol (PHY) LC, SAXS patterns 35 
showed the hexagonal and cubic phases, respectively.  Bioavailability was significantly 36 
enhanced after oral administration of LCs prepared by GMO than after diosgenin alone.  The 37 
bioavailability was father improved with the combination of LC and β-CD than LC and water. 38 
 39 
Keywords: Diosgenin, liquid crystal, glyceryl monooleate, phytantriol, β-cyclodextrin, oral 40 
administration.  41 
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1. Introduction 42 
Many chemical compounds have recently been synthesized and characterized to develop 43 
new drug candidates in pharmaceutical industries.  However, more than 40% of these 44 
compounds have been terminated due to poor dissolution and/or biomembrane permeability 45 
(Prentis et al., 1988; Venkatesh and Lipper, 2000).  Poorly water-soluble compounds have 46 
been detected not only in medicines, but also in dietary and cosmetic supplements.  47 
Nevertheless, few studies have investigated the pharmacokinetics of these supplements.  Thus, 48 
the pharmacokinetics of these supplements need to be investigated to improve their oral 49 
absorption.  Diosgenin, which is extracted from wild yam (Dioscorea villosa) and fenugreek 50 
(Trigonella foenum greaceum), is a steroidal saponin (Taylor et al., 2000; Hooker, 2004).   In 51 
our previous study, we demonstrated that the solubility of diosgenin in water and its 52 
bioavailability were poor (Okawara et al., 2010).  The oral administration of diosgenin to 53 
diabetic rats significantly decreased plasma glucose levels (Pari et al., 2012).  Furthermore, 54 
diosgenin decreased serum total cholesterol, triglyceride, and low-density lipoprotein 55 
cholesterol levels in rats fed a high-fat diet (Gong et al., 2010).  Diosgenin has been 56 
established as a raw material for the production of steroidal hormones in the pharmaceutical 57 
industry (Applezweig, 1969).  It has also been used as dietary supplement in hormone 58 
replacement therapy for menopausal women (Russell et al., 2002; Benghuzzi et al., 2003).  59 
Orally administrated diosgenin was shown to improve skin thickness in ovariectomized mice, 60 
and enhanced DNA synthesis in a human 3D equivalent model (Tada et al., 2009).  61 
Furthermore, it inhibited melanogenesis in B16 melanoma cells by activating the 62 
phosphatidylinositol-3-kinase pathway (Lee et al., 2007).  Based on these findings, diosgenin 63 
is considered as an active element in cosmeceutical and dietary supplements.  We previously 64 
reported that the bioavailability of diosgenin was only 6% in rats.  We have been 65 
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investigating ways by which to improve its low bioavailability.  Our findings suggested that 66 
diosgenin and β-cyclodextrin (β-CD) formed 1:2 molar ratio inclusion complexes that 67 
improved the bioavailability of diosgenin to 45% in rats (Okawara et al., 2013).  However, 68 
the β-CD inclusion complex has to be suspended in water when administered to rats, and it 69 
also takes time to prepare the complex. 70 
Liquid crystals (LCs) are semisolids with crystalline structures combining the properties 71 
of both solid and liquid states (Yamada et al., 2011).  Commonly encountered phases in LCs 72 
include the lamellar, bicontinuous cubic, and inverse hexagonal phases (Clogston et al.,2000).  73 
LCs are easily formed by various amphipathic lipids such as glyceryl monooleate (GMO) and 74 
phytantriol (PHY) in excess amounts of water (Lee et al., 2009; Costa-Balogh et al., 2010).  75 
Our previous report must be the first one for the LC using PHY (Yamada et al., 2011).  Many 76 
studies reported that the oral administration of LC enhanced the bioavailability of poorly 77 
water-soluble drugs (Boyd et al., 2007; Nguyen et al., 2011; Lian et al., 2011).  In this study, 78 
we prepare self-assembly LCs and dispersed LCs including diosgenin, and physicochemical 79 
measurements for LCs were performed using Zetasizer and small angle X-ray scattering 80 
(SAXS).  LCs were administered to rats and their pharmacokinetic parameters were calculated 81 
for diosgenin.  Furthermore, we elucidated the interaction between LC formation and β-CD 82 
solution for oral administration to rats. 83 
 84 
2. Materials and methods 85 
2.1. Materials 86 
Diosgenin was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.).  Polyoxyethylene 87 
hydrogenated castor oil 60 (HCO-60) was supplied from Nikko Chemicals (Tokyo, Japan).  88 
Sodium pentobarbital was obtained from Kyoritsu Seiyaku (Tokyo, Japan).  GMO and PHY 89 
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were obtained from Tokyo Chemical Industry (Tokyo, Japan).  β-CD, 6-methyl diosgenin, and 90 
other chemicals were obtained from Wako Pure Chemical Industries (Osaka, Japan).   91 
 92 
2.2. Preparation of liquid crystals 93 
LC was formed using GMO or PHY and an equal or greater volume of water, and 94 
involved a transition from the lamella phase to the hexagonal phase, and finally to the cubic 95 
phase by heating (Lee et al., 2009).  To determine the solubility of diosgenin in lipids, each 96 
lipid was added to a tube with an excess amount of diosgenin.  The mixture was heated at 37°C 97 
in a heating block to facilitate solubilization using a vortex mixer.  Mixtures were shaken in a 98 
thermo-controlled incubator at 37°C for 2 h.  After reaching equilibrium, each tube was 99 
centrifuged at 15,000 ×g for 5 min and the supernatant was collected.  After dilution, the 100 
content of diosgenin was determined using a liquid chromatography mass spectrometry (LCMS) 101 
system.  Separation was achieved by an MXY01-01 (Michrom Biosources Inc., CA, U.S.A.) 102 
with a TSK gel ODS-100V column (2.0×50 mm, 3 µm) (TOSOH, Tokyo, Japan) at room 103 
temperature.  The mobile phase consisted of methanol (90%) and H2O (10%) containing 10 104 
mM ammonium acetate.  The flow rate was set to 150 µL/min and detection was performed 105 
using an LCQ DECA XP Plus mass spectrometer (Thermo Fisher Scientific Inc., MA, U.S.A.).  106 
Self-assembly LCs were prepared by dissolving diosgenin in each lipid at 5 mg/mL by heating 107 
at 70°C.  108 
 109 
2.3. SAXS measurement 110 
Equal volumes of water and self-assembly LC were mixed prior to measurements being 111 
taken.  These samples were heated at 70°C, and mixed to homogenization using a vortex mixer.  112 
SAXS measurements were performed on a NANO-Viewer (Rigaku) with PILATUS 100K/RL 113 
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2D detector.  The X-ray source was Cu Kα radiation, wavelength 1.54 Å, operating at 45 kV 114 
and 110 mA.  The sample-to-detector distance was chosen to be 375 mm.  Each sample was 115 
placed between polyether ether ketone membranes and exposed for 10 min. 116 
 117 
2.4. Dispersibility of LC 118 
Dispersed LC was prepared by adding 10-fold of water to self-assembly LC.  The 119 
mixture was heated on a heating block at 70°C, and shaken using a vortex mixer.  These 120 
samples were centrifuged at 15,000 ×g for 5 min, and the water phase was collected.  Samples 121 
were diluted 1000-fold in water prior to measurements being taken.  Particle diameters and 122 
dispersion were measured by dynamic light scattering measurements on a Nano-ZS ZEN 3600 123 
Zetasizer (Malvern, Worcestershire, UK) with water. 124 
 125 
2.5. Solubility study 126 
In the solubility study, 10-fold of water or 4 mM β-CD solution were added to 127 
self-assembly LC, and mixed at 37°C for 5 days.  These samples were centrifuged at 15,000×g 128 
for 5 min, and the water phases were collected.  The contents of diosgenin and each lipid were 129 
determined using an LCMS system after filtration with a 0.2 µm membrane filter (ADVANTEC, 130 
Tokyo, Japan) and dilution.  131 
 132 
2.6. Animals 133 
Male Wistar rats (200 to 250 g) were provided from Japan SLC (Hamamatsu, Shizuoka, 134 
Japan).  Animals were housed under a 12 h light and dark cycle in a temperature-controlled 135 
room (23 ± 2°C).  They had free access to food and water.  The animal care protocol was 136 
approved by the Animal Care and Use Committee of Josai University (Saitama, Japan). 137 
7 
 
 138 
2.7. Pharmacokinetic studies 139 
Intravenous and oral administration studies were performed to compare the 140 
pharmacokinetic parameters of diosgenin and its LC.  Rats were fasted from at least 12 h prior 141 
dosing to 4 h after dosing.  In the intravenous administration protocol, diosgenin was dissolved 142 
in saline containing 1% HCO-60, and 121 µg/kg (body weight) of diosgenin was injected into 143 
the tail vein.  For oral administration, a diosgenin suspension of 5 mg/mL or self-assembly LC 144 
formulation containing an equivalent amount of diosgenin was prepared and administered at a 145 
dose of 2 mL/kg (body weight).  Diosgenin was suspended in saline containing 1% HCO-60.  146 
Self-assembly LC was prepared by dissolving diosgenin in PHY or GMO.  In the LC group, 147 
self-assembly LC and equal amounts of water or β-CD solution (24 mM) were simultaneously 148 
administrated.  Blood was collected from the tail vein into heparinized tubes at times ranging 149 
from 0 to 96 h, and was immediately separated by centrifugation.  In a previous study, skin 150 
levels of diosgenin peaked 6 h after its oral administration (Okawara et al., 2013).  Skin 151 
samples were taken from the entire abdomen 6 h after the oral administration.  Each sample 152 
was stored at -30°C until analyzed.  153 
 154 
2.8. Analytical procedure 155 
6-methyl diosgenin was used as an internal standard to assess diosgenin levels in plasma 156 
and skin samples.  Samples were added to methanol and extraction was achieved by sonication 157 
for 20 min at 37°C.  These samples were centrifuged at 15,000 × g for 5 min and the 158 
supernatants were collected.  The content of diosgenin was determined by an LCMS system 159 
with a Tosoh TSK gel ODS-100V column (2.0×50 mm, 3 µm) at room temperature. 160 
 161 
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2.9. Pharmacokinetics and statistical analysis 162 
Pharmacokinetics analysis was performed with nonlinear least-squares fitting.  The area 163 
under the plasma concentration-time curve (AUC) was calculated using the linear trapezoidal 164 
rule.  The absolute bioavailability was determined as AUCpo/AUCiv, using mean AUC values 165 
for oral and intravenous doses.  Tukey’s multiple comparison tests was used to assess the 166 
significance of differences between groups.  A p value of less than 0.05 was considered 167 
significant. 168 
169 
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3. Results 170 
3.1. SAXS measurements 171 
The phase behavior of LCs made from GMO or PHY was confirmed by SAXS 172 
measurements.  Representatives of the SAXS profiles of LCs are shown in Figure 1.  SAXS 173 
curves revealed the presence of a hexagonal phase (with reflections spaced at √1, √3, and √4; 174 
Fig. 1A) for GMO LC and bicontinuous cubic phase (reflections at √2, √3, √4, √6, √8, √9, √10, 175 
and √12; Fig. 1B) for PHY LC.  The phase behavior of LCs was not affected by the presence 176 
of diosgenin (see the lines a and b).  These results confirmed that these lipids formed LCs 177 
when mixed with water at room temperature.  178 
 179 
3.2 Dispersibility of LC 180 
The particle diameter and dispersion of LCs were measured to confirm their conditions in the 181 
gastric and intestinal tract.  The particle diameters of LCs made from GMO and PHY are listed 182 
in Table 1.  Each particle diameter of LCs was nearly 100-200 nm and its distribution in water 183 
remained unchanged in the presence of diosgenin.  PHY LC showed larger diameter than 184 
GMO LC both with and without diosgenin.  Although the diameter of a particle of PHY 185 
became small by diosgenin, it is unknown for details. 186 
 187 
3.3. Solubility study 188 
The solubility of diosgenin and lipids in water or β-CD solution are listed in Table 2.  189 
The solubility of diosgenin was increased by β-CD and GMO, whereas it was decreased by 190 
PHY.  It is suggested that the lower release of diosgenin was caused by PHY melting point 191 
(70°C).  More diosgenin was released from LCs in β-CD solution than in water.  192 
Correspondingly, the solubilities of GMO and PHY in water were increased by β-CD. 193 
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 194 
3.4. Pharmacokinetics of diosgenin self-assembly LC with CD solution after oral 195 
administration 196 
Fig. 2 shows the mean plasma diosgenin concentration-time curves after oral 197 
administration of self-assembly LC and CD solution in Wistar rats.  Table 3 shows the 198 
calculated pharmacokinetics parameters.  The maximum plasma concentration of diosgenin 199 
(Cmax) after oral administration of GMO LC was higher than of the diosgenin suspension.  200 
The time to reach the maximum plasma concentration (Tmax) of GMO LC was similar to that 201 
of the suspension (Fig. 2A).  However, the Tmax was significantly higher and Cmax was 202 
significantly lower with PHY LC than with the diosgenin suspension (Fig. 2B).  Plasma 203 
concentrations were higher in the β-CD combination groups than in self-assembly LC with 204 
water.  Diosgenin bioavailability was significantly higher after the oral administration of GMO 205 
LC with β-CD solution than after GMO LC with water. 206 
 207 
3.5. Skin distribution of diosgenin 208 
The distributions of diosgenin in skin were determined after the oral administration of 209 
diosgenin or its LC and summarized in Figure 3.  The contents of diosgenin in skin 6 h after its 210 
administration alone, with β-CD solution, GMO LC, GMO LC with β-CD solution, PHY LC, 211 
and PHY LC with β-CD solution were 23.95, 90.70, 178.21, 371.79, 11.39, and 8.93 ng/g skin, 212 
respectively.  The content of diosgenin was significantly higher in the GMO LC with β-CD 213 
solution groups than in the diosgenin suspension.  214 
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4. Discussion 215 
We initially prepared diosgenin LCs and characterized their physical properties.  216 
Self-assembly LCs and dispersed LCs were prepared and analyzed using SAXS and Zetasizer.  217 
The SAXS data demonstrated that GMO and PHY, which dissolved diosgenin, formed 218 
hexagonal and cubic phases, respectively, when mixed with equal volumes of water at room 219 
temperature.  The particle diameter of LCs was nearly 100-200 nm in water.  These results 220 
suggested that GMO and PHY LCs are dispersed in the gastrointestinal tract as microdroplets 221 
(Jin et al., 2013).  The solubility of diosgenin was increased by β-CD and GMO.  Further 222 
enhancements in its solubility were obtained when LCs were combined with β-CD solution.  223 
These results indicated that β-CD solution enhanced the release of diosgenin and lipids from 224 
LCs. 225 
Plasma diosgenin levels were relatively low after oral administration of the diosgenin 226 
suspension, and were similar to those in our previous study (Okawara et al., 2013).  However, 227 
GMO LC significantly improved its bioavailability.  Previous studies reported that GMO LC 228 
were strongly bioadhesive and stimulated entrapped-drug permeation through the intestinal 229 
mucosa (Geraghty et al., 1997; Lai et al., 2009).  Tmax was higher with PHY LC than with the 230 
diosgenin suspension.  Nguyen et al. suggested that PHY LC retained in the gastrointestinal 231 
tract may slowly diffuses, while suppressing drug release; this is consistent with the results of 232 
the present study (Nguyen et al., 2010).  Furthermore, the combination of self-assemble LC 233 
and β-CD solution enhanced the plasma concentration and bioavailability more than LC alone.  234 
Different patterns were confirmed in plasma diosgenin concentration–time curves after the oral 235 
administration of GMO LC and PHY LC.  These may have been caused by differences in the 236 
melting points of lipids than changes in LC phases.  The skin distribution of diosgenin was 237 
higher after the oral administration of GMO LC and GMO LC with β-CD solution than that of 238 
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the diosgenin suspension.  A lower skin content was observed after the oral administration of 239 
PHY LC and PHY LC with β-CD solution.  A previous study reported a correlation between 240 
plasma concentrations of diosgenin and skin content (Okawara et al., 2013).  These findings 241 
suggested that PHY LC and PHY LC with β-CD solution maintained the skin content of 242 
diosgenin over 48 h.  Although further research is needed, self-assembly LCs may control the 243 
release of drugs included in LC.  Furthermore, the results of the present study indicate that 244 
β-CD solution improve the release of drugs from LCs. 245 
 246 
Conclusions 247 
The aim of this study was to improve the bioavailability of diosgenin.  We prepared 248 
diosgenin LCs and evaluated their combined effect with β-CD solution.  The solubility, 249 
bioavailability, and skin distribution of diosgenin were much better with LC in β-CD solution 250 
than that with LC alone.  These results indicate that β-CD solution increases diosgenin and 251 
lipid release from LCs.   252 
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Figure legends 315 
Figure 1.  SAXS profiles for GMO (A) and PHY (B).  The profiles are shown for LC with 316 
diosgenin (a) and without diosgenin (b).  LCs were prepared by mixing equal volumes of 317 
self-assembly LC and water at 70°C. 318 
 319 
Figure 2.  Plasma profiles after the oral administration of diosgenin: A- (○), diosgenin 320 
suspension; (□), GMO self-assembly LC with water; (■), GMO self-assembly LC with β-CD 321 
solution; B-(○), diosgenin suspension; ( ), PHY self-assembly LC with water; and (▲), PHY 322 
self-assembly LC with β-CD solution.  Each point shows the mean ± S.E. of 3 to 8 323 
experiments.  *: p<0.05 significantly different from the diosgenin suspension.  †: P<0.05 324 
significantly different from its self-assembly LC (Tukey’s test). 325 
 326 
Figure 3.  Skin distribution of diosgenin after oral doses of diosgenin and LC.  Skin samples 327 
were collected 6h after the oral administration of diosgenin and LC.  Each column shows the 328 
mean ± S.E. of 3 to 4 experiments.  *: p<0.05 significantly different from the diosgenin 329 
suspension (Tukey’s test).  330 
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Tables 339 
Table 1.  Particle diameter of LCs. 340 
 
Particle diameter (nm) 
Without diosgenin With diosgenin 
GMO 112.1 ± 0.5 117.6 ± 0.5 
PHY 212.1 ± 0.8 138.1 ± 0.5 
Self-assembly LCs were dispersed in water at 37°C.  The particle diameter of each formation 341 
was measured after centrifugation and dilution. 342 
 343 
 344 
 345 
Table 2.  Solubility of diosgenin and lipids in water or β-CD solution. 346 
 
Solubility of diosgenin 
in water（ng/mL）  
CD/Water 
ratio 
Solubility of lipids 
in water（µg/mL）  
CD/Water 
ratio 
Water CD solution Water CD solution 
GMO 2,210 ± 460 8,360 ± 400 3.77 409 ± 40 464 ± 112 1.14 
PHY 4.50 ± 1.11 3,550 ± 220 789 3.99 ± 0.48 16.9 ± 1.9 4.24 
Without lipids 10.5 ± 3.5 3,260 ± 170 310 - - - 
 Diosgenin was dissolved in GMO or PHY at 5 mg/mL.  A ten-fold amount of water or 4 mM 347 
β-CD solution was added, and mixed at 37°C for 5 days.  Each value shows the mean ± S.E. of 348 
3 experiments. 349 
 350 
 351 
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Table 3.  Pharmacokinetic parameters after the oral administration of the diosgenin suspension 352 
and self-assembly LCs with water or CD solution. 353 
 AUCpo 
(ng･h/mL) 
Cmax 
(ng/mL) 
Tmax 
(h) 
Bioavailability 
(%) 
Enhancement 
ratio 
GMO LC + CD 4403 ± 132*† 239 ± 2* 5.6 ± 0.2 47.1 ± 1.4*† 6.2 
GMO LC 2934 ± 465* 164 ± 36* 6.0 ± 1.2 31.4 ± 5.0* 4.1 
PHY LC + CD 1000 ± 191 11.4 ± 1.7* 22 ± 3* 10.2 ± 1.8 1.4 
PHY LC 633.9 ± 62.0 8.38 ± 0.52* 22 ± 4* 7.30 ± 0.05 0.9 
Diosgenin 711.4 ± 53.3 23.0 ± 1.9 5.0 ± 0.7 7.61 ± 0.51 1.0 
Each value shows the mean ± S.E. of 3 to 4 experiments.  *: p<0.05 significantly different 354 
from diosgenin.  †: p<0.05 significantly different from its LC. (Tukey’s test). 355 
 356 
